MODULAR FIELD-STABLE BIO-ARTIFICIAL BLOOD SUBSTITUTE

    公开(公告)号:US20250064724A1

    公开(公告)日:2025-02-27

    申请号:US18718963

    申请日:2022-11-18

    Abstract: Bio-artificial blood substitutes are provided for intravenous medical use to restore or increase tissue perfusion and oxygen delivery in a pre-hospital or hospital setting. The bio-artificial blood substitutes comprise three modular components (polyethylene glycol (PEG) polymers to increase perfusion, a hemoglobin-based oxygen carrier (HBOC) plus L-arginine to prove oxygen carrying capacity, and a lyophilized fibrinogen or plasma component to provide hemostasis potential, all of which are administered sequentially in modules to treat low perfusion states with possible coagulopathy as seen in blood loss and shock. The three solutions are stable at ambient temperature and are well-suited for use in the field, e.g., when immediate, critical care is needed such as on the battlefield, during natural disasters or other mass casualty events. Other use may include clinical need for transfusion or for peri-surgical resuscitation in patients unable to receive standard blood products.

    NATIVE CELL MEMBRANE NANOPARTICLES
    93.
    发明申请

    公开(公告)号:US20250026892A1

    公开(公告)日:2025-01-23

    申请号:US18581769

    申请日:2024-02-20

    Abstract: Provided is a functionalized polymer useful for extracting, isolating, and/or purifying membrane proteins with their native protein structures being retained. Also provided are a Native Cell Membrane Nanoparticle (NCMN) system which contains the above functionalized polymer and a membrane protein and a method to characterize and/assess the native structure of the membrane protein.

Patent Agency Ranking